BioSpace News Archive

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.

Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced on Tuesday it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. (Nasdaq: MSFT) to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing.

Patients, caregivers and doctors can access and share trusted bone and joint health information available on OrthoInfo.org

The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent infection with the virus that causes COVID-19 disease..

Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs

VolitionRx Limited announced it will host a conference call on Friday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business update.

Jupiter Orphan Therapeutics, Inc. announced that it is strengthening its Scientific Advisory Board with the addition of Dr. Charbel Moussa, and created a new advisory position in patient advocacy by the appointment of Mark Dant..

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today reported that more than 5,000 people with amyotrophic lateral sclerosis (ALS) have received the treatment with RADICAVA ® (edaravone) in North America since the therapy was approved by the U.S. Food and Drug Administration (FDA) on May 5, 2017 .

Industry veteran joins McKesson after more than 13 years at National Comprehensive Cancer Network

Antengene Corporation announced a broadened partnership and territory expansion agreement with Karyopharm Therapeutics Inc. for development and commercialization of four oral novel drugs and drug candidates to support its mission of treating patients beyond borders.